Globe News Wire
27 Jul 2026, 09:21 UTC · 7w ago
Verdict
Headline takes no side. We score ITM +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA has a PDUFA goal date of August 28, 2026, for ITM's lead drug candidate 177 Lu-edotreotide (ITM-11).
So whatFDA approval decisions are primary binary catalysts for biotech valuations and revenue potential.
More positive than 98% of claims this week
ITM has established Lumara Bio as a dedicated oncology therapeutics division to manage commercial readiness and pipeline development.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 62% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company is establishing a new division to prepare for the commercial launch of a drug candidate currently under FDA review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
−2.3%
Price is moving against the score
$44.81 vs $45.87 close before publication (Jul 24) · not market-adjusted
ITM chart →
